The following is a summary of the Tempus AI, Inc. (TEM) Q4 2025 Earnings Call Transcript:
Financial Performance:
Tempus AI reported Q4 2025 total revenue growth of over 33%, significantly enhanced by the acquisition of Ambry.
The Diagnostic business saw notable unit growth: Oncology at 29% and Hereditary at 23%.
Data business (licensing and applications) grew impressively, with Insights up 69% in the quarter.Tempus AI's net revenue retention was 126%, indicating strong customer retention and expanded revenue per existing customer.
Guided to $1.59 billion revenue and approximately $65 million of positive adjusted EBITDA for the upcoming year.
Business Progress:
Tempus AI is focusing on expanding its AI capabilities, particularly with Paige Predict and other AI models, to enhance diagnostics and data business offerings.
Secured significant contracts with large pharma, contributing to a TCV greater than $1.1 billion.
Moving forward with significant advancements in MRD testing and expecting major developments in tumor-naive assays.
Financial Guidance:
For FY 2026, Tempus AI anticipates revenue to align with 25% long-term growth targets, with strong contributions from both diagnostics and data businesses.
Data business projects around 40% growth this upcoming quarter.
Highlighted a potential upside in ASP of over $500 in the diagnostics area from migrations and adjustments.
Opportunities:
Tempus AI's unique position with a vast, proprietary data set and widespread connection to hospitals provides a significant competitive advantage.
Opportunities to enhance and expand offerings through AI and data-driven insights in the diagnostics field.
Strong partnerships with big pharma can lead to increased demand and strengthening of data services.
Risks:
Adjustments and advancements in the MRD testing field may face reimbursement delays or requirements that could affect financial results.
There is a continued need for enhancing tumor-naive assay capabilities to stay competitive.
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
